Company Overview
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.10.
Recent Developments
- Dec 2025 Revenue of $8.27M (-5.4% YoY); net profit $-17.52M.
- Trailing 12 Months Year-on-year growth — revenue +14.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.46% |
| 1 Year: | 14.10% |
Stock Price Performance
| 1 Year: | -99.59% |
| 6 Months: | -98.26% |
| 3 Months: | -84.99% |
| 1 Month: | -47.13% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)30.29 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 99.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NUWE Nuwellis, Inc. PHARMA | 0.79 | 0.00 | $2.51M | 0.00% | - | - | 8.46% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 864.00K | 957.00K | 1.04M | 1.10M | 1.36M | 1.22M | 1.68M | 1.25M | 1.63M | 1.86M | 1.90M | 1.92M | 2.51M | 1.85M | 1.93M | 2.21M | 2.06M | 1.83M | 2.08M | 2.41M | 1.86M | 2.19M | 2.37M | - | 1.90M | 1.73M | 2.22M | 2.42M | 2.40M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 837.00K | 767.00K | 772.00K | 770.00K | 719.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 834.00K | 1.20M | 878.00K | 966.00K | 1.51M | 1.12M | 1.10M | 1.06M | 1.26M | 1.07M | 1.15M | 1.38M | 1.19M | 1.47M | 1.66M | - | 1.07M | 958.00K | 1.45M | 1.65M | 1.68M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.13M | 3.86M | 4.14M | 4.10M | 6.25M |
| Operating Income | -6.17M | -6.37M | -6.66M | -6.11M | -6.99M | -6.34M | -6.27M | -4.55M | -3.98M | -4.06M | -2.31M | -2.50M | -2.86M | -4.35M | -4.18M | -4.25M | -4.72M | -4.43M | -4.51M | -4.57M | -3.92M | -4.26M | -5.22M | -4.73M | -5.25M | -4.42M | -4.30M | -3.92M | -5.85M | -5.02M | -3.16M | -4.75M | -2.32M | -1.53M | - | -3.06M | -2.91M | -2.70M | -2.44M | -4.57M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.99M | -1.95M | 672.00K | -2.33M | -4.53M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 10.55M | 0 | 0 | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.01M | -12.55M | 468.00K | -2.42M | -4.54M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00K | 4.00K | 0 | 0 | 0 |
| Net Income | - | - | - | - | - | - | - | - | -4.19M | -3.92M | -940.00K | -2.46M | -2.85M | -4.35M | -4.18M | -4.24M | -4.73M | -4.43M | -4.51M | -4.57M | -3.92M | -4.26M | -5.22M | -4.73M | -5.27M | -4.47M | -4.29M | -3.87M | -6.49M | -4.84M | -3.37M | -4.33M | -7.72M | 2.36M | - | -3.01M | -12.55M | 468.00K | -2.42M | -4.54M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.54 | -3.10 | -2.08 | -1.62 | -0.72 | -0.75 | -42.45 | -40.67 | -36.72 | -5.76 | -127.65 | -63.27 | -24.11 | -791.82 | 73.23 | - | -1,014.30 | -2,133.80 | 19.60 | -52.50 | -73.15 |
| R&D Expense | 3.75M | 4.06M | 4.41M | 3.81M | 4.87M | 3.99M | 4.55M | 3.21M | 2.57M | 1.74M | 308.00K | 327.00K | 367.00K | 479.00K | 643.00K | 985.00K | 1.31M | 1.30M | 1.11M | 864.00K | 885.00K | 871.00K | 947.00K | 1.17M | 1.73M | 1.11M | 1.11M | 928.00K | 1.43M | 1.50M | 1.12M | 1.33M | 558.00K | 486.00K | - | 550.00K | 675.00K | 603.00K | - | 1.73M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 59.00K | 295.00K | 59.00K | 1.29M | 3.55M | 5.00M | 5.51M | 7.44M | - | 8.54M | 8.86M | 8.74M | 8.27M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | 3.79M | 3.88M | 3.06M | 3.15M |
| Gross Profit | - | - | - | - | - | - | - | - | - | 4.06M | - | 4.75M | 4.98M | 5.68M | 5.12M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 21.93M | 22.61M | 16.66M | 16.23M |
| Operating Income | -16.56M | -14.87M | -22.87M | -25.79M | -25.96M | -15.66M | -14.81M | -17.04M | -18.11M | -17.03M | - | -17.17M | -17.63M | -10.99M | -11.11M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | -4.90M | -16.36M | -5.24M | -6.55M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | 9.25M | 3.48M | 5.61M | 10.55M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | -14.52M | -20.20M | -11.16M | -17.52M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 9.00K | 8.00K | 5.00K | 5.00K |
| Net Income | -16.20M | -14.06M | -21.76M | -25.59M | -26.58M | -15.79M | -13.38M | -17.03M | -18.11M | -15.84M | - | -14.53M | -20.21M | -11.16M | -17.52M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -10.67 | - | -947.80 | -16,934.40 | -3,571.09 | -888.65 |
| R&D Expense | 11.20M | 8.00M | 13.50M | 16.87M | 17.67M | 8.11M | 1.48M | 3.05M | 4.67M | 3.67M | 4.98M | 4.34M | 5.42M | 3.21M | 2.71M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.43M | 15.04M | 55.23M | 32.37M | 24.45M | 7.47M | 18.45M | 8.78M | 5.60M | 20.01M | - | 24.67M | 9.77M | 9.86M | 6.12M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 22.77M | 8.21M | 8.86M | 5.19M |
| Cash & Equivalents | 12.35M | 6.56M | 14.22M | 54.14M | 31.29M | 23.11M | 1.32M | 15.60M | 5.48M | 1.28M | 14.44M | - | 17.74M | 3.80M | 5.09M | 1.08M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 2.66M | 2.00M | 1.72M | 1.91M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 1.41M | 1.95M | 1.73M | 1.49M |
| Total Liabilities | - | 2.83M | 2.09M | 3.50M | 3.16M | 12.28M | 5.23M | 2.22M | 2.84M | 3.61M | 3.69M | - | 12.32M | 6.56M | 3.33M | 3.49M |
| Current Liabilities | - | 2.83M | 2.09M | 3.50M | 3.16M | 8.00M | 3.26M | 2.09M | 2.84M | 3.35M | 3.58M | - | 4.69M | 3.17M | 2.56M | 3.03M |
| Long Term Debt | - | - | - | - | - | 3.88M | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | 984.00K | 760.00K | 545.00K | 328.00K |
| Total Equity | 12.09M | 4.60M | 12.95M | 51.73M | 29.21M | 12.17M | 1.76M | 16.24M | 5.94M | 1.99M | 16.32M | - | 12.36M | 3.21M | 6.53M | 2.63M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 10 | 110 | 2.98K | 48.18K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | -16.29M | -11.92M | -14.56M | -16.37M | -16.57M | - | -15.15M | -17.94M | -9.59M | -10.81M |
| Investing Cash Flow | - | - | - | - | - | -4.12M | -259.00K | -198.00K | -490.00K | -267.00K | - | 14.73M | 330.00K | -60.00K | -90.00K |
| Financing Cash Flow | - | - | - | - | - | -1.36M | 26.45M | 4.65M | 12.66M | 30.02M | - | 9.42M | 3.68M | 10.96M | 6.94M |
| Capital Expenditure | -451.00K | -158.00K | -293.00K | -351.00K | -199.00K | -117.00K | -259.00K | -198.00K | -490.00K | -298.00K | - | -122.00K | -248.00K | -60.00K | -90.00K |
| Free Cash Flow | - | - | - | - | - | -16.41M | -12.18M | -14.76M | -16.86M | -16.87M | - | -15.27M | -18.18M | -9.65M | -10.90M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | 9.00M | -13.92M | 1.31M | -3.96M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | 54.5% | - | 55.7% | 56.2% | 64.9% | 62.0% |
| Operating Margin % | - | - | -38,764.4% | -8,741.4% | -43,996.6% | -1,215.1% | -416.9% | -340.9% | -328.5% | -228.8% | - | -201.0% | -198.9% | -125.7% | -134.3% |
| Net Margin % | - | - | -36,878.0% | -8,673.6% | -45,055.9% | -1,225.1% | -376.6% | -340.8% | -328.7% | -212.8% | - | -170.0% | -228.0% | -127.7% | -211.9% |
| ROE % | -352.4% | -108.6% | -42.1% | -87.6% | -218.4% | -898.8% | -82.4% | -286.9% | -910.3% | -97.0% | - | -117.5% | -629.4% | -171.0% | -666.2% |
| ROCE % | -360.4% | -114.8% | -44.2% | -88.3% | -157.8% | -371.9% | -90.5% | -287.0% | -804.4% | -103.7% | - | -85.9% | -267.2% | -150.4% | -359.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Sabby Management, LLC | 0.45% | 16.37K | $14.69K |
| 2 | UBS Group AG | 0.12% | 4.42K | $3.96K |
| 3 | SBI Securities Co., Ltd. | - | 4 | $3 |
| 4 | Tower Research Capital LLC (TRC) | - | 138 | $123 |
| 5 | Morgan Stanley | - | 35 | $31 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NUWE
Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical
Agreement expands Nuwellis’ pediatric and critical care portfolio and provides a milestone-based pathway to U.S. distributionMINNEAPOLIS and MADISON, Wis., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technolog…
Nuwellis Inc (NUWE) (Q2 2026) Earnings Call Highlights: Revenue Surges 14% and Installed Base ...
Nuwellis Inc (NUWE) reports strong U.S. growth and improved gross margins while advancing its pediatric label expansion and strategic cardiorenal platform initiatives.
Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin
Recent capital raise and warrant exercises extend cash runway through second quarter of 2027 Conference call begins at 9:00 a.m. Eastern time today MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical tech…
Nuwellis Accelerates Digital Transformation of the Aquadex® Platform with EHR Connectivity and Enhanced User Interface
Expands interoperability, enhances clinician workflow, and establishes the digital foundation for future software-enabled extracorporeal therapiesMINNEAPOLIS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical techno…
Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Nuwellis also received $3.1 Million from the Exercise of Previously Issued Warrants from the June 2026 Public OfferingMINNEAPOLIS, July 31, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical tech…
Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy
Peer-reviewed research demonstrates epoprostenol maintained circuit performance without observed bleeding events or increased vasoactive support in critically ill pediatric patientsMINNEAPOLIS, July 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, In…
NUWE — Frequently Asked Questions
What is the current share price of Nuwellis, Inc. (NUWE)?
As of 2026-09-19 21:16 PDT, Nuwellis, Inc. (NUWE) trades at $0.79 on NasdaqCM. Its 52-week range is $0.73 to $220.50.
What is the market capitalisation of NUWE?
Nuwellis, Inc. (NUWE) has a market capitalisation of $2.51M on NasdaqCM.
Is NUWE a good stock to buy?
This page provides a data-driven analysis of Nuwellis, Inc. (NUWE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.